| Name | Title | Contact Details |
|---|
NGInstruments is a Warsaw, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A nutritional ingredient manufacturer, Kemin is a privately held corporation, founded in 1961 by R.W. and Mary Nelson.
“We are a part of the circle of life. It`s as touching and important to be a part of the end of life as it is to be at the beginning. We provide our patients dignity, comfort and quality of life at the end of their journey. Our job is so much more about life than death! Being present during this sacred time is truly and honor, a calling. “ -Jane, LPH Registered Nurse **** Chapters Health System is committed to enhancing the lives of those affected by advancing age or illness. Through our comprehensive system of healthcare choices, we deliver expert care and heartfelt support to guide the community during the aging and end-of-life journey. From hospice and palliative care for adults and children suffering with life-threatening or life-limiting illnesses to in-home and community-based services for frail but independent seniors, Chapters Health offers a wide range of support services along life`s ever-changing landscape. By providing choices, education and guidance, Chapters Health helps enhance the lives of those affected by advancing age or illness. Chapters Health System includes Chapters Health Palliative Care, Chapters Health Pharmacy, Chapters Health Staffing, Good Shepherd Hospice, HPH Home Health, HPH Hospice and LifePath Hospice.
Cardinal Fitness is a Merrillville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.